[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Essen\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":669},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,39,66,93,116,144,172,199,223,242,270,296,320,341,363,384,414,437,463,498,526,557,592,619,647],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100644081","theranostic-pet-for-target-validation-and-tumor-detection-100644081",false,"NCT07664410","Theranostic PET for Target Validation and Tumor Detection","TheranosticPET","Inclusion Criteria:\n\n1. PET imaging with a theranostic PET tracer scheduled for staging or restaging of tumor types as part of clinical routine\n2. Age ≥ 18 years\n\nExclusion Criteria:\n\n1. Patient cannot give consent for the study\n2. Patient cannot lie flat or tolerate PET imaging\n3. Unwillingness or inability to comply with study and follow-up procedures\n4. Condition of patient which is critical to participate in this study in the discretion of the investigators\n5. Pregnant, lactating, or breast-feeding women","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","12 Months","OBSERVATIONAL","Patients are referred for theranostic PET using different tracers as part of clinical routine for tumor staging, re-staging, and therapy planning to our department.\n\nThe aim of this study is to collect data on the expression of target molecules\u002Freceptors, proportion of PET positive tumor regions, positive predictive value, detection rate, reproducibility, and impact on clinical management of theranostic PET\u002FCT or PET\u002FMRI using novel theranostic PET tracers or other established PET tracers that are performed in theranostic concepts on patients receiving this imaging modality as part of clinical standard both at initial diagnosis and restaging before treatment decisions.\n\nPrimary Endpoint:\n\nAssociation between PET uptake intensity in theranostic PET and histopathologic expression of the respective molecular target.",[25],"Solid Malignancies","RECRUITING","2026-06-17",{"date":29,"type":30},"2026-06-24","ACTUAL",{"date":32,"type":30},"2025-09-23",{"date":34,"type":20},"2035-09-23",{"name":36,"class":37},"University Hospital, Essen","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100624434","mental-health-and-suicidality-in-glioblastoma-patients-in-germany-100624434","NCT07409584","Mental Health and Suicidality in Glioblastoma Patients in Germany","Mental Health and Suicidality in Glioblastoma Patients in Germany - a Multicenter Observational Study (SHINE-GLIO Study)","SHINE-GLIO","Inclusion Criteria:\n\n* Diagnosis of glioblastoma, IDH wild-type (CNS WHO classification of 2021)\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Participants with clinically significant aphasia or language barrier as assessed by the investigator\n* History of other malignant tumors\n* Known tumor predisposition syndrome (e.g., Li-Fraumeni syndrome, Cowden syndrome, etc.)",{"count":48,"type":20},176,"The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety symptoms.",[51],"Glioblastoma (GBM)",[53,54,55,56],"glioblastoma","suicidality","depression","observational","2026-05-13",{"date":59,"type":30},"2026-05-18",{"date":61,"type":30},"2026-03-18",{"date":63,"type":20},"2027-12-01",{"name":36,"class":37},6,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":38},"100499007","improving-adherence-to-statin-therapy-through-a-medication-management-application-100499007","NCT05777655","Improving Adherence to Statin Therapy Through a Medication Management Application","Improving Adherence to Statin Therapy Through a Medication Management Application (STAPP)","STAPP","Inclusion Criteria:\n\n* Age \\>18 years\n* Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +\u002F- 10 days of enrolment)\n* Statin naivety\n* LDL-C \\>100 mg\u002Fdl. No older than 21 days\n\nExclusion Criteria:\n\n* Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia)\n* Patient has no own smartphone (no device provided for this study)\n* Prior drug therapy to lower LDL-C within the last 30 days\n* Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \\\u003C6 months\n* Use of a digital therapy management application (including mediteo or mediteo m+) within the last month\n* Participation in another interventional trial\n* Pregnancy\n* Inability or unwillingness to provide informed consent",{"count":75,"type":20},250,"INTERVENTIONAL",[78],"NA","Interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, Mediteo GmbH, Heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.",[81],"Atherosclerosis",[83,84],"Smartphone Application","Medication Therapy Management","2026-04-28",{"date":87,"type":30},"2026-05-04",{"date":89,"type":30},"2023-02-17",{"date":91,"type":20},"2028-11-28",{"name":36,"class":37},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":76,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100634975","phase-4-efficacy-of-zoster-vaccination-in-glioblastoma-patients-100634975","NCT07546669","Efficacy of Zoster Vaccination in Glioblastoma Patients","Herpes Zoster Vaccine and Autologous CMV-specific T Cells as an Immunomodulatory Adjunct to Standard Neurosurgical Resection Radiochemotherapy in Glioblastoma","STARGATE","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible for enrolment into the trial:\n\n* At least 18 years of age\n* Written informed consent of the subject\n* Life expectancy at least 3 months\n* Participants of child-bearing age must use effective contraception\n* Indication for definitive radiotherapy of glioblastoma or adjuvant radiation therapy of glioblastoma resection cavity according to interdisciplinary tumor board consensus and after radiation oncologists evaluation\n* Histopathologically proven glioblastoma\n* Incorporation of pre-neurochirurgical \u002F-treatment PET\u002FCT or\u002F and PET\u002FMRI findings into the radiation therapy plan if patient undergoes PET\u002FCT or\u002F and PET\u002FMRI\n\nExclusion Criteria:\n\nSubjects will not be included in the study if any of the following criteria apply. General Exclusion Criteria:\n\n* Subjects not able to give consent\n* Subject without legal capacity who is unable to understand the nature, scope, significance, and con- sequences of this clinical trial\n* Simultaneously participation in another clinical trial or participation in any clinical trial involving ad- ministration of an investigational medicinal product within 30 days prior to clinical trial beginning\n* Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk may confound the trial results or may interfere with the subject's participation in this clinical trial\n* Known or persistent abuse of medication, drugs or alcohol\n* Contraindications for radiotherapy (including active inflammatory disease)\n* Known hypersensitivity against vaccine contra herpes zoster, or its constituents\n* Gliomatosis cerebri at time of enrollment on any imaging or proved by histopathology\n* Synchronous secondary malignancy\n\nExclusion criteria regarding special restrictions for females as the treatment procedures require the highest degree of safety for the child:\n\n* Current or planned pregnancy or nursing women\n* Females of child-bearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study duration (such as oral, injectable, or implantable contracep- tives, or intrauterine contraceptive devices) unless they are surgically sterilized \u002F hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases\n\nIndication-specific exclusion criteria in order to guarantee the highest degree of safety of all treatment procedures from a medical point of view:\n\n* Primary infra-tentorial located glioblastoma (justification: specific subgroup of patients with different prognosis)\n* Significant comorbidities at baseline, which would prevent possible chemotherapy, including:\n\n  i. Platelet count \\\u003C 100\u002Fnl ii. Absolute neutrophil count (ANC) \\\u003C 1.5\u002Fnl iii. AST or ALT \\> 3 times the upper limit of normal iv. Total bilirubin above the normal range v. Serum creatinine \\> 1.7 mg\u002Fdl\n* Patients with clinically significant liver-, renal- or blood disorder\n* Patients with known additional significant neurological disease (e.g. primary seizure disorder\\*, de-mentia, progressive degenerative neurological disease, meningitis or encephalitis, hydrocephalus with increased intracranial pressure)\n* Patients with brain tumor-related epilepsy, seizure-free under antiepileptic therapy are eligible\n* Active implanted medical device (e.g. deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators and programmable shunts) or documented clinically signifi- cant arrhythmias\n* History of HIV infection",{"count":102,"type":20},230,[104],"PHASE4","In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma.\n\nWe hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.",[51],"NOT_YET_RECRUITING","2026-04-16",{"date":110,"type":30},"2026-04-23",{"date":112,"type":20},"2027-01-02",{"date":114,"type":20},"2030-12-31",{"name":36,"class":37},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":133,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":38},"100620597","multimodal-analysis-of-endomyocardial-biopsies-100620597","NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.",{"count":123,"type":20},216,"The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[126,127,128,129,130,131,132],"Heart Transplantation","Dilated Cardiomyopathy (DCM)","Hypertrophic Cardiomyopathy (HCM)","Myocarditis, Pericarditis","Amyloidosis Cardiac","Cardiomyopathies","Sarcoidosis of the Heart",[134,135],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":138,"type":30},"2026-01-22",{"date":140,"type":30},"2025-10-27",{"date":142,"type":20},"2028-09-30",{"name":36,"class":37},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":38},"100619349","quality-of-life-and-the-influence-of-stress-on-the-postoperative-course-of-patients-after-device-implantation-100619349","NCT07343466","Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation","Klinische Studie Zur Untersuchung Der Lebensqualität Und Des Einflusses Von Stress Auf Den Postoperativen Verlauf Von Patienten Nach Device-Implantation","Inclusion Criteria:\n\n* Patients of legal capacity with an indication for device implantation (pacemaker, ICD, CRT, event recorder) who present at the Department of Cardiology and Angiology at the University Hospital Essen and consent to participate in the study will be included.\n\nExclusion Criteria:\n\n* none",{"count":152,"type":20},300,"The project \"Investigating Quality of Life and the Influence of Stress on the Postoperative Course of Patients After Device Implantation\" aims to investigate the relationship between stress and the postoperative healing process of patients who have had a medical device implanted. These devices include pacemakers for the treatment of bradycardia, implantable cardioverter-defibrillators (ICDs) for the treatment of tachycardia in primary and secondary prevention, and cardiac resynchronization therapy (CRT) devices and event recorders. The study will analyze the influence of stress on the postoperative course, potential complications, and overall quality of life. A combination of medical examinations and surveys will be used to analyze how psychological stress influences the physical healing process and which measures can contribute to improving quality of life and treatment success. The surgical procedure for implanting devices is not part of the study; this is an observational study.",[155],"Quality of Life (QOL) and Impact of Stress",[157,158,159,160,161,162,163,164],"Impact of Stress","postoperative course","ICD","CRT","Pacemaker","Event-Recorder","prospektive","Quality of life","2026-01-06",{"date":136,"type":30},{"date":168,"type":30},"2025-02-04",{"date":170,"type":20},"2029-07-15",{"name":36,"class":37},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":76,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100576399","phase-2-preoperative-amivantamab-or-amivantamab-and-carboplatinpemetrexed-treatment-in-patients-with-resectable-non-small-cell-lung-cancer-harboring-oncogenic-egfr-mutations-neopredict-egfr-100576399","NCT06784791","Preoperative Amivantamab or Amivantamab and Carboplatin\u002FPemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","NEOpredict-EGF","Inclusion Criteria:\n\n1. Patients with histologically (core biopsy) or cytologically (e.g., bronchoscopy-guided biopsy) confirmed non-small-cell lung cancer (NSCLC) eligible for anatomic resection, with the following specifications:\n\n   * Clinical stages I B, II or selected stage III A (T3 N1, T4 with satellite nodule in the same lung N0\u002FN1, selected T1a-T2b N2 cases considered suitable for primary surgical approach by the multidisciplinary tumor board) according to UICC 8th edition\n   * Confirmation of an oncogenic EGFR mutation (EGFR p.L858R, EGFR exon 19 in-frame deletion, EGFR exon 20 in-frame insertions, EGFR p.S768I, EGFR p.L861Q, EGFR p.G719x - additional EGFR mutations with clinically validated oncogenicity and susceptibility to amivantamab may be eligible following discussion and approval by the coordinating investigator in his capacity as sponsor representative) by validated assaytechnology (e.g., diagnostic NGS or PCR-based genotyping, adhering to quality standards defined by the nNGM Lung Cancer biomarker standard operating procedure (version 007 or higher) in Germany, or equivalent in Belgium and the Netherlands) in a pretreatment biopsy (primary tumor or lymph node metastasis)\n2. Males and females, ages \\>= 18 years, inclusive\n\n   * A participant of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[hCG\\]) within 24 hours prior to the start of study treatment and must agree to further serum or urine pregnancy testing during the study.\n   * A participant must be (as defined in Appendix IV: Contraceptive Guidance and Collection of Pregnancy Information) either of the following:\n\n     * Not of childbearing potential\n     * Of child-bearing potential and practicing true abstinence during the entire period of the study, including up to 6 months after the last dose of study treatment is given\n     * Of childbearing potential and practicing 2 methods of contraception, including 1 highly effective user independent method and a second method (examples of highly effective methods of contraception are located in Appendix IV: Contraceptive Guidance and Collection of Pregnancy Information).Participant must agree to continue contraception throughout the study and through 6 months after the last dose of study treatment.\n     * Note: If the childbearing potential changes after start of the study (e.g., participant of childbearing potential who is not heterosexually active becomes active, premenarchal participant experiences menarche) the participant must begin birth control, as described above\n   * A participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study treatment.\n   * A participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 6 months after receiving the last dose of study treatment. A participant who is sexually active with a partner of childbearing potential must agree to use a condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository and their partner must also be practicing a highly effective method of contraception (i.e., established use of oral, injected, or implanted hormonal methods of contraception; placement of an intrauterine device \\[IUD\\] or intrauterine hormone-releasing system \\[IUS\\]). If the participant is vasectomized, they must still use a condom (with or without spermicide) for prevention of passage of exposure through ejaculation, but their partner is not required to use contraception.\n   * A participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 6 months after receiving the last dose of study treatment.\n   * Participant must be willing and able to adhere to the lifestyle restrictions specified in this protocol.\n3. ECOG performance status ≤ 1\n4. Exclusion of extensive mediastinal lymph node metastases (multilevel N2, N3) by PET\u002FCT and\u002For invasive mediastinal lymph node staging by EBUS-TBNA and\u002For staging mediastinoscopy as performed by institutional guidelines.\n5. Exclusion of distant metastases by standard of care imaging studies, which include but are not limited to PET\u002FCT or PET\u002FMRI, or CT or MRI of thorax, abdomen including pelvic region, and bone scan. Asymptomatic brain metastases will be excluded by MRI or contrastenhanced CT as indicated by institutional guidelines and patient factors.\n6. Measurable target tumor (pre RECIST 1.1) prior to preoperative study therapy using standard imaging techniques.\n7. Sufficient pulmonary function (ppFEV1\\>30%, ppDLCO\\>30%) to undergo curative lung cancer surgery. Exercise tests should be performed in all patients with FEV1 or DLCO \\\u003C60% of normal. In case of cardiopulmonary exercise testing, the following basic cut-off values for VO2-peak should be considered: \\>75% predicted or \\>20 mL·kg-1·min-1 qualify for pneumonectomy; \\\u003C35% predicted or \\\u003C10 mL·kg-1·min-1 indicate high risk for any resection. There is insufficient evidence to recommend specific cut-off values for lobectomy or segmentectomy.\n8. Adequate hematological, hepatic and renal function parameters:\n\n   * Leukocytes ≥ 2,000\u002Fmm³, platelets ≥ 100,000\u002Fmm³, absolute neutrophil count (ANC) ≥ 1,500\u002FμL, hemoglobin ≥ 9 g\u002FdL (stage 1) or 10 g\u002FdL (stage 2)\n   * Anti-platelet therapy (such as but not limited to clopidogrel) should be discontinued pre-operatively according to local standards. If this therapy cannot be interrupted due to severe cardiovascular comorbidity, patient is ineligible for the trial\n   * Adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the upper limit of normal (ULN) (unless receiving anticoagulation therapy). Patients receiving warfarin\u002Fphenprocoumon or direct oral anticoagulants are to be bridged according to local standards and have achieved stable coagulation profile prior to surgery\n   * Serum creatinine ≤ 1.5 x upper limit of normal and creatinine clearance \\>45 mL\u002Fmin as measured or calculated by Cockcroft- Gault formula for estimated creatinine clearance (Appendix VII)\n   * Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.0 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal. Subjects with Gilbert's syndrome can be enrolled if conjugated bilirubin is within normal limits\n9. Sufficient cardiac left ventricular defined as LVEF ≥ 50% documented either by echocardiography or MUGA (echocardiography preferred, MUGA not used in German sites) within 6 months before first administration of study drug.\n10. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures.\n\nExclusion Criteria:\n\n1. Lung cancer entity and stage other than defined by the inclusion criteria.\n2. Absence of a predictive oncogenic EGFR mutation (EGFR p.L858R, EGFR exon 19 in-frame deletion, EGFR exon 20 in-frame insertions, EGFR p.S768I, EGFR p.L861Q, EGFR p.G719x - additional EGFR mutations with clinically validated oncogenicity and susceptibility to amivantamab may be eligible following discussion and approval by the coordinating investigator in his capacity as sponsor representative) in apretreatment biopsy (primary tumor or metastasis).\n3. Active or past medical history of interstitial lung disease (ILD)\u002Fpneumonitis, including drug- or radiation-induced ILD\u002Fpneumonitis.\n4. Subjects with a condition requiring continuous systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted.\n5. Subjects who have undergone organ transplant or allogeneic stem cell transplantation.\n6. ppFEV1\\\u003C30%, ppDLCO\\\u003C30%, ppVO2max \\\u003C 10 ml\u002Fmin\u002Fkg or other criteria of functional inoperability per local guidelines.\n7. History of uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:\n\n   * Myocardial infarction (MI), NSTEMI, coronary artery bypass grafting, or stroke\u002Ftransient ischemic attack (TIA) within the 6 months prior to consent\n   * Uncontrolled angina within the 3 months prior to consent\n   * Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)\n   * Prolonged corrected QTc interval by Fridericia's \\> 470 msec\n   * Uncontrolled persistent hypertension (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg)\n   * Clinically significant deep vein thrombosis or pulmonary embolism within 1 month prior to study treatment (clinically nonsignificant thrombosis or incidental, asymptomatic pulmonary embolism are not exclusionary)\n   * Pulmonary hypertension (sPAP \\>35 mmHg; only measured if clinically indicated and\u002For mandated per local guidelines)\n8. History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association \\[NYHA\\] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion etc.).\n9. Cardiovascular or pulmonary disease-related requirement for daily supplemental oxygen.\n10. History of two or more myocardial infarctions or two or more coronary revascularization procedures.\n11. Patients with active neurological disease should be excluded.\n12. Active malignancy or a prior malignancy within the past 3 years. Patients with the following conditions are not excluded from participation:\n\n    o Patients with adequately resected skin cancer (melanoma or non-melanoma), cervical carcinoma in-situ, intestinal polyps not containing invasive cancer, treated breast carcinoma in-situ or bladder carcinoma in-situ that are considered completely cured, and patients with isolated elevation in prostate-specific antigen or low risk prostate cancer managed with active surveillance or watchful waiting in the absence of radiographic evidence of metastatic prostate cancer.\n13. Known history of positive test for human immunodeficiency virus (HIV- 1 and HIV-2) or known acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV-1 and HIV-2 must be performed at screening.\n14. Positive test result for hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg).\n\n    o Note: participants with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at screening (i) a negative HBsAg and (ii) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing.\n15. Positive hepatitis C antibody (anti-HCV).\n\n    o Note: participants with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.\n16. History of other clinically active infectious liver disease\n17. Uncontrolled diabetes mellitus\n18. Ongoing or active infection (includes infection requiring treatment with antimicrobial therapy \\[participants will be required to complete antibiotics 1 week prior to starting study treatment\\] or diagnosed or suspected viral infection.\n19. Psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements.\n20. Any ophthalmologic condition that is clinically unstable.\n21. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of amivantamab, carboplatin or pemetrexed, or may affect the interpretation of the results, or may render the patient at high risk from treatment complications.\n22. Receipt of live attenuated vaccine within 30 days prior to the first dose of study medication.\n23. Serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment\n24. The patient has undergone major surgery within 28 days prior to enrollment except staging mediastinoscopy, diagnostic VATS or implantation of a venous port-system, or has not recovered from prior surgery.\n25. Any other concurrent preoperative antineoplastic treatment including irradiation\n26. Pregnant women\n27. Breastfeeding women\n28. Insufficient cardiac left ventricular function defined as LVEF\\\u003C50% by echocardiography (outside Germany: or MUGA scan)\n29. A confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent\n30. Subjects with history of severe or life-threatining (grade 3 or 4) infusion-related reactions to prior antibody therapy or immune therapy\n31. Prior treatment with amivantamab or any EGFR tyrosine kinase inhibitor\n32. Participation in another interventional clinical study within the last 3 months prior to inclusion or simultaneous participation in other interventional clinical studies\n33. Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety.\n34. Any contraindications against amivantamab (stages 1 and 2), carboplatin or pemetrexed (stage 2)",{"count":180,"type":20},20,[182],"PHASE2","The primary objective of this study is to determine the feasibility of four weeks of preoperative antibody therapy with amivantamab. Amivantamab will be administered as monotherapy (stage 1), and combined with carboplatin\u002Fpemetrexed chemotherapy (stage 2). Study treatment is followed by standard of care surgery, and (if clinically indicated) standard of care adjuvant therapy (chemotherapy, radiotherapy, EGFR tyrosine kinase inhibitor therapy) in patients with early stage or locally advanced non-small-cell lung cancer harboring oncogenic EGFR mutations who are eligible for curative resection.",[185],"Lung Cancer (NSCLC)",[187,188,189],"NSCLC","Lung cancer","non-small-cell lung cancer","2025-08-28",{"date":192,"type":30},"2025-08-29",{"date":194,"type":30},"2024-11-06",{"date":196,"type":20},"2027-12-31",{"name":36,"class":37},4,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":208,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":38},"100604812","hybrid-florbetaben-petmri-for-imaging-of-cardiac-amyloidosis-100604812","NCT07154381","Hybrid Florbetaben PET\u002FMRI for Imaging of Cardiac Amyloidosis","Monocentric Observational Trial for Florbetaben PET\u002FMRI Hybrid Imaging in Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 40 years\n* proven Amyloidosis (ATTR or AL)\n* Women: negative pregnancy test less than weeks prior imaging.\n\nExclusion Criteria:\n\n* Patients receiving amyloidosis-specific treatment prior study inclusion.\n* Patients participating in other clinical trails for treatment of Amyloidosis.\n* Pregnancy\n* Contraindiactions for MRI (eGFR\\\u003C30ml\u002Fmin\u002F1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).\n* inability of consent\n* Refusal of consent","40 Years",{"count":5,"type":20},"36 Months","Exploration of prognostic parameters in 18F-Florbetaben PET\u002FMRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).",[211],"Cardiac Amyloidosis",[213,214],"PET\u002FMRI","Florbetaben","2025-08-26",{"date":217,"type":30},"2025-09-04",{"date":219,"type":30},"2019-12-09",{"date":221,"type":20},"2025-12",{"name":36,"class":37},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":38},"100604813","cardiac-amyloid-deposits-and-heart-dysfunction-in-alzheimers-disease-100604813","NCT07154394","Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease","Investigation of Cardiac Amyloid Deposits as a Cause of Cardiac Dysfunction in Alzheimer's Disease (Untersuchung Von Kardialen Amyloidablagerungen Als Ursache Einer Funktionseinschränkung Des Herzens Bei Alzheimer Demenz)","Inclusion Criteria:\n\n* Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease\n* No contraindications to undergo an MRI examination\n* No contraindications to undergo an Amyloid PET scan\n\nExclusion Criteria:\n\n* Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)\n* Patients with pronounced cardiac preconditions\n* Pregnant and breastfeeding women",{"count":231,"type":20},15,"This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.\n\nThe study will conduct additional PET\u002FMRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.\n\nThis could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.",[234,235,211],"Dementia, Alzheimer Type","Mild Cognitive Impairment",{"date":217,"type":30},{"date":238,"type":30},"2022-08-15",{"date":240,"type":20},"2025-09-14",{"name":36,"class":37},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":76,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},"100602977","distrupt-stiffness-trial-100602977","NCT07130526","Distrupt Stiffness Trial","Trial to Investigate the Shockwave Intravascular Lithotripsy (IVL) on Vascular Compliance in Heavily Calcified Femoropopliteal Disease (PACSS 2-4)","Inclusion Criteria:\n\n* Peripheral artery disease\n* Severe Calcification PACCS 2,3 and 4\n* Target lesions in distal EIA, CFA, prox. SFA or PA\n* Clinical diagnosis of chronic, symptomatic lower limb ischemia as defined by Rutherford 2, 3, 4 and 5\n* Planed peripheral intervention TASC A-D\n* Subject must be between 18 and 85 years old\n* Willing to comply with the specified follow-up evaluation\n* Written informed consent prior to any study procedures\n\nExclusion Criteria:\n\n* Target lesions with no optimal visualization in ultrasound\n* Instent-Restenosis\n* Thrombolysis within 72 hours prior to the index procedure\n* Aneurysm formations in the femoral artery or popliteal artery\n* Concomitant hepatic insufficiency, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy\n* Unstable angina pectoris at the time of the enrolment\n* Recent myocardial infarction or stroke \\\u003C 30 days prior to the index procedure\n* Life expectancy less than 12 months\n* Septicemia at the time of enrolment\n* Known or suspected active infection at the time of the index procedure, excluding an infection of a lower extremity wound of the target limb\n* Known or suspected allergies or contraindications to aspirin, clopidogrel or heparin","85 Years",{"count":251,"type":20},40,[78],"Typical symptoms of PAD include exercise-induced pain in the legs (known as intermittent claudication), which can significantly limit pain-free walking. In more advanced stages, pain may also occur at rest. Additionally, the development of chronic, hard-to-heal wounds-especially on the feet and toes-is possible. These wound healing impairments are caused by the insufficient supply of oxygen and nutrients to the affected tissues.\n\nThe underlying cause of PAD is usually atherosclerosis, a pathological change in the vessel walls due to the accumulation of fats, calcium, and connective tissue. These deposits lead to stiffening and narrowing of the arteries, severely restricting blood flow. Major risk factors for the development of PAD include widespread chronic conditions such as diabetes mellitus, hyperlipidemia (elevated blood lipid levels, e.g., cholesterol), arterial hypertension (high blood pressure), obesity, and tobacco use.\n\nVarious therapeutic options are available for the treatment of PAD. In addition to conservative therapy (such as supervised exercise training, pharmacological blood thinning, and risk factor management), interventional, minimally invasive treatment using catheter-based techniques is frequently employed. In such procedures, a thin catheter is guided through the vascular system to the affected area of the leg artery. Depending on the type and extent of the arterial narrowing or calcification, one of the following techniques may be applied:\n\nBalloon angioplasty: Dilation of the vessel using an inflatable balloon. Lithoplasty: Application of shockwaves to break down calcifications in the arterial wall.",[255,256],"PAD - Peripheral Arterial Disease","PAD",[258,259,260],"pad","peripheral artery disease","intravascular lithotripsy","2025-08-15",{"date":263,"type":30},"2025-08-19",{"date":265,"type":30},"2025-07-01",{"date":267,"type":20},"2026-06-20",{"name":36,"class":37},2,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":277,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":280,"conditions":281,"keywords":283,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":38},"100584280","essen-amyloidosis-registry-100584280","NCT06887283","Essen Amyloidosis Registry","EAR","Inclusion Criteria:\n\n* Suspected or confirmed amyloidosis (any)\n* Written informed consent to participate in the study\n* Age 18 years and above\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of written informed consent",true,{"count":279,"type":20},400,"The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry aims to improve the understanding of disease progression, diagnostic pathways, and treatment outcomes. The registry is hosted at the University Hospital Essen and follows patients longitudinally. Inclusion is open to all patients with suspected or confirmed amyloidosis who provide informed consent.",[282,130],"Amyloidosis; Systemic",[284,285,286,287,288],"Amyloidosis","Transthyretin","Light chain amyloidosis","Neuropathy","Cardiomyopathy",{"date":290,"type":30},"2025-08-21",{"date":292,"type":30},"2024-05-08",{"date":294,"type":20},"2029-07-01",{"name":36,"class":37},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":38},"100584266","impact-of-stress-on-cardiovascular-events-in-patients-with-peripheral-arterial-disease-100584266","NCT06887101","Impact of Stress on Cardiovascular Events in Patients with Peripheral Arterial Disease","Inclusion Criteria:\n\nDiagnosis of lower extremity PAD based on:\n\n* Limb bypass surgery or\n* aorta-femoral bypass surgery or\n* percutaneous transluminal angioplasty revascularization of the iliac or infrainguinal arteries or\n* limb or foot amputation for arterial vascular disease or\n* intermittent claudication and one or more of either an ankle brachial index (ABI) of less than 0.90 or a peripheral artery stenosis (≥50%) documented by angiography or duplex ultrasound or carotid revascularization or asymptomatic carotid artery stenosis of at least 50% diagnosed by duplex ultrasound or angiography\n\nExclusion Criteria:\n\n* atrial fibrillation\n* high premature ventricular contractions burden\n* pacemaker with constant ventricular pacing\n* antiarrhythmic drugs class I or III",{"count":152,"type":20},"Atherosclerotic cardiovascular disease is the leading cause of morbidity and mortality worldwide. Patients with peripheral arterial disease are at increased risk suffering from major adverse cardiac and limb events. Acute and chronic stress affect the cardiovascular system. Long-term negative stressors lead to cardiovascular diseases and can aggravate already existing cardiovascular diseases. However, current guidelines on cardiovascular disease prevention highlight stress as a cardiovascular risk factor there is a lack of consensus about the definition and measurement of stress. The aim of the proposed trial is to evaluate different stress measuring methods in patients with PAD depending on the occurrence of cardiovascular events.",[305],"Peripheral Arterial Disease",[307,308,309,310,311],"vascular diseases","cardiovascular diseases","ischemia","arteriosclerosis","stress","2025-03-14",{"date":314,"type":30},"2025-03-20",{"date":316,"type":30},"2023-04-21",{"date":318,"type":20},"2026-12-31",{"name":36,"class":37},{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":22,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":38},"100377606","essen-coronary-artery-disease-registry-100377606","NCT04196712","Essen Coronary Artery Disease Registry","ECAD registry","Inclusion Criteria:\n\n* Patients undergoing invasive coronary angiography at the West German Heart and Vascular Center\n\nExclusion Criteria:\n\n* None",{"count":328,"type":20},55000,"3 Years","The ECAD registry is a registry of patients undergoing coronary angiography at the West German Heart and Vascular Center. The registry anticipates to determine predictors of patient outcome after coronary angiography.",[332],"Coronary Artery Disease","2024-12-18",{"date":335,"type":30},"2024-12-24",{"date":337,"type":30},"2019-09-01",{"date":339,"type":20},"2027-06-30",{"name":36,"class":37},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":277,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":38},"100398544","influence-of-hypoxic-induced-factors-in-patients-with-hereditary-hemorrhagic-telangiectasia-100398544","NCT04469517","Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia","Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)","Inclusion Criteria:\n\n* diagnosed HHT (genetic testing and\u002F or fulfill at least 3 Curacao Criteria)\n* older than 17 years\n* ability to consent\n\nExclusion Criteria:\n\n* if inclusion Criteria are not met",{"count":349,"type":20},100,"Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.",[352],"Hereditary Hemorrhagic Telangiectasia",[354],"hereditary hemorrhagic telangiectasia","2024-12-05",{"date":357,"type":30},"2024-12-06",{"date":359,"type":30},"2020-08-10",{"date":361,"type":20},"2026-10-01",{"name":36,"class":37},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":38},"100535079","pet-guided-radiotherapy-for-patients-with-small-cell-lung-cancer-100535079","NCT06247163","PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.","Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.","PET-ART","Inclusion Criteria:\n\n* Histopathologic confirmation\n* Limited disease\n\nExclusion Criteria:\n\n* Other histology than small cell lung cancer\n* Further tumor diagnosis\n* ECOG 3 or worse\n* Extensive disease\n* stage IV",{"count":372,"type":20},30,"There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society\u002FCancer Aid\u002FAWMF",[375],"Small Cell Lung Carcinoma","2024-09-25",{"date":378,"type":30},"2024-09-27",{"date":380,"type":30},"2024-02-22",{"date":382,"type":20},"2029-06-22",{"name":36,"class":37},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":76,"phases":393,"briefSummary":394,"conditions":395,"keywords":399,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":38},"100535554","optimization-of-radiation-protection-through-genomic-analyses-100535554","NCT06253338","Optimization of Radiation Protection Through Genomic Analyses","Optimization of Radiation Protection Through Genomic Analyses in the Analysis of Changes in Cells of the Hematopoietic System Before and During High Dose External Beam Radiotherapy","ORtogether","Inclusion Criteria:\n\nECOG 0\u002F1 no prior treatment no prior cancer diagnosis thoracic or head and neck cancer\n\nExclusion Criteria:\n\nprior treatment (chemotherapy, radiotherapy, etc.) prior cancer diagnosis",{"count":372,"type":20},[78],"The long-term goal is to define \"signatures\" in the form of genomic changes through sequence analyses of genomic DNA using modern Next Generation Sequencing (NGS) methods, which\n\n1. determine the radiation exposure of humans.\n2. provide information about the exposure (dose).\n3. determine the radiation quality.\n4. predict the repair capacity and radiation resistance of an individual.",[396,397,398],"DNA","Cancer","Radiation",[396,400,401,402,403,404,405,406,407],"cancer","sequencing technologies","lymphocyte","genomic","loosely ionizing radiation","Linear Energy Transfer","outcome","thoracic radiotherapy",{"date":378,"type":30},{"date":410,"type":30},"2024-06-01",{"date":412,"type":20},"2030-01-15",{"name":36,"class":37},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":76,"phases":423,"briefSummary":424,"conditions":425,"keywords":430,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":38},"100532697","adaptive-radiotherapy-in-head-and-neck-tumor-patients-100532697","NCT06216171","Adaptive Radiotherapy in Head and Neck Tumor Patients","Prospective Randomized Study on Adaptive Radiotherapy in Head and Neck Tumor Patients (Pro- Head and Neck -ART, ProHEART)","ProHEART","Inclusion Criteria:\n\nECOG 0\u002F1 No prior cancer treatment\n\nExclusion Criteria:\n\nECOG 2-4 Prior cancer treatment",{"count":372,"type":20},[78],"Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016\u002FS1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.",[426,427,428,429],"Head and Neck Neoplasms","Head and Neck Cancer","Adaptive Radiotherapy","Optimization",[426,427,428,429],{"date":378,"type":30},{"date":433,"type":30},"2024-01-25",{"date":435,"type":20},"2028-01-30",{"name":36,"class":37},{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":76,"phases":447,"briefSummary":448,"conditions":449,"keywords":453,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":38},"100532577","prospective-validation-of-adaptive-radiotherapy-art-in-patients-with-head-and-neck-tumors-100532577","NCT06214611","Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors","Adaptive Radiotherapy in the Treatment of Patients With a Histologically Confirmed Malignant Tumor in the Head and Neck Region: Prospective Validation of ART in Patients With HNT (Prospektive Validierung Der ART Bei Patientinnen Und Patienen Mit Kopf-Hals Tumoren,)","ART in HNT","Inclusion Criteria:\n\n1. ECOG 0-1\n2. Histopathology confirmation\n3. Compliance\n4. Tumor in the head and neck region\n5. Indication for radiotherapy\n\nExclusion Criteria:\n\n1\\. Pregnancy",{"count":446,"type":20},50,[78],"Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.",[427,428,398,450,451,452],"Optimized Treatment","Protection of Organs at Risk","Dysphagia Reduction",[427,428,454,455,456],"Protection of organs at risk","Optimized treatment","Dysphagia reduction",{"date":378,"type":30},{"date":459,"type":30},"2023-11-15",{"date":461,"type":20},"2027-12-15",{"name":36,"class":37},{"id":464,"slug":465,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":472,"conditions":473,"keywords":481,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":497},"100387864","hiv-heart-aging-study-100387864","NCT04330287","HIV-HEART Aging Study","A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk, New Cardiovascular Events and the Cardiovascular Diseases in HIV-infected Patients: 15 Year Follow up","HIVH","Inclusion Criteria:\n\n* Age \\> 18 years\n* Known HIV-infection\n* Signed informed consent\n\nExclusion Criteria:\n\n* Acute cardiovascular disease\n* Unstable hemodynamic status in the three weeks before inclusion\n* Pregnancy",{"count":19,"type":20},"The HIV\u002FHEART Aging study (HIVH) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (CVD) in HIV-infected patients. The study population includes outpatients from specialized HIV-care units of the German Ruhr region, who were at least 18 years of age, were known to have a HIV-infection and exhibited a stable disease status within 4 weeks before inclusion into the trial. From March 2004 (Pilot phase) to October 2022 (15 year Follow-up) 1858 HIV+ patients were recruited in a consecutive manner. The standardised examinations included a targeted assessment of medical history and physical examination. Blood was drawn for comprehensive laboratory tests including HIV specific parameters (CD4 cell count, HIV-1 RNA levels) and cardiovascular items (lipid concentrations, BNP values and renal parameters). Furthermore, non-invasive tests were performed during the initial visit, including additional heart rate and blood pressure measurements, electrocardiogram (ECGs) and transthoracic echocardiography (TTE). Examinations were completed in accordance with previously defined standard operating procedures. CVD were defined as coronary, cerebrovascular, peripheral arterial disease, heart failure or cardiac vitium.",[474,475,476,477,478,479,480],"HIV Infections","Coronary Disease","Myocardial Infarction","HIV Encephalopathy","Aging","Heart Failure","Weight Gain",[482,483,484,478,479,485,486,487,488],"HIV","AIDS","Antiretroviral therapy","coronary heart desease","myocardial infarction","HIV-associated neurocognitive disorders","weight gain","2024-07-29",{"date":491,"type":30},"2024-07-30",{"date":493,"type":30},"2020-05-11",{"date":495,"type":20},"2025-12-31",{"name":36,"class":37},5,{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":76,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":38},"100544843","exercise-in-patients-with-advanced-non-small-cell-lung-cancer-100544843","NCT06374160","Exercise in Patients With Advanced Non-small Cell Lung Cancer","Better Symptom Control With Exercise in Patients With Advanced Non-small Cell Lung Cancer","BREATH","Inclusion Criteria\n\n* Patients with histologically confirmed non-small cell lung carcinoma in UICC stages IIIB and IV\n* First- or second-line therapy (inclusion up to 28 days after the first cycle) in palliative intention\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria\n\n* Severe cardiopulmonary disease (EF\\\u003C30%)\n* Newly occurring or progressive uncontrolled CNS (central nervous system) metastases\n* Expected life expectancy \\\u003C 3 months\n* Bone metastases with acute risk of fracture\n* ECOG (Eastern Cooperative Oncology Group) performance status \\> 2\n* Acute pulmonary embolism\n* Acute myocardial infarction\n* Requiring surgery for aortic aneurysm\n* Tension pneumothorax\n* Lack of proficiency in the German language\n* Active infection",{"count":507,"type":20},104,[78],"Lung cancer is one of the most common types of cancer in Germany, with 56,839 new cases and 45,072 deaths annually. Approximately 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage and suffer from comorbidities and symptoms such as fatigue, tiredness, and loss of strength. The standard first-line treatment for metastatic NSCLC includes platinum-based chemoimmunotherapy followed by immunotherapy maintenance. Exercise can have positive effects on symptoms such as shortness of breath, fatigue, quality of life, and physical fitness. However, there is a lack of current scientific evidence for the effectiveness of exercise in advanced lung cancer patients. No current trial investigated exercise in advanced NSCLC receiving immunotherapy so far.\n\nThe BREATH-study is a prospective 3-arm randomized controlled trial (RCT). In total, the investigators plan to recruit 104 patients. A 2:1:1 randomization will be performed with three study groups: a control group and two exercise therapy groups (strength+endurance exercise\u002Fonly endurance exercise). One group receives individual endurance training and the other group a combination of individual endurance and strength training. Both treatment groups will be treated twice a week for 12 weeks. The control group will initially receive standard treatment without exercise for 12 weeks and will then be randomized into one of the other two study groups with exercise twice a week for 12 weeks. This approach allows for a sufficiently large sample for comparisons between exercise therapy and the control group, as well as between the two exercise therapy approaches.\n\nThe primary aim is to investigate the impact of exercise on V02peak. Secondarily endpoints aim to investigate changes in physical function, patient related outcomes and cardiac function before and after exercise.",[511,512,513,514,515,516,517],"Advanced Lung Carcinoma","First Line Treatment","Second Line Treatment","NSCLC Stage IV","NSCLC Stage IIIB","Palliative Treatment","NSCLC Stage IIIC","2024-04-15",{"date":520,"type":30},"2024-04-18",{"date":522,"type":20},"2024-05-01",{"date":524,"type":20},"2026-08-31",{"name":36,"class":37},{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":11,"sex":534,"minAge":17,"maxAge":4,"enrollmentInfo":535,"targetDuration":537,"studyType":22,"phases":4,"briefSummary":538,"conditions":539,"keywords":544,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":38},"100540698","promise-pet-registry-on-psma-pet-and-outcome-in-prostate-cancer-100540698","NCT06320223","PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer","PROMISE-PET","Inclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer.","MALE",{"count":536,"type":20},10000,"10 Years","Background:\n\nPROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.\n\nNeed:\n\nImproved prognostication across various stages of prostate cancer is needed for management guidance and study design.\n\nAim:\n\n1. To assess the prognostic value of PSMA PET\n2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages\n\nInclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer",[540,541,542,543],"Prostate Cancer","PET\u002FCT","Survivorship","PSMA",[540,541,542,543,545,546,547,548],"Nuclear Medicine","Imaging","Oncology","Urology","2024-03-15",{"date":551,"type":30},"2024-03-20",{"date":553,"type":30},"2024-03-05",{"date":555,"type":20},"2035-03-05",{"name":36,"class":37},{"id":558,"slug":559,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":11,"sex":565,"minAge":17,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":76,"phases":567,"briefSummary":568,"conditions":569,"keywords":575,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":38},"100533802","adaptive-radiotherapy-in-patients-with-gynecological-tumors-100533802","NCT06230549","Adaptive Radiotherapy in Patients With Gynecological Tumors","Prospective Randomized Validation of Adaptive Radiotherapy in Patients With Gynecological Tumors and Indication for Radiotherapy","ProART","Inclusion Criteria:\n\nECOG 0-1 confirmation by histophatology MR of the pelvis staging\n\nExclusion Criteria:\n\nRecurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1","FEMALE",{"count":372,"type":20},[78],"Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.",[570,428,398,571,429,572,573,574],"Gynecological Tumor","Curative Treatment","Adaptive Radiation Therapy","Image Guided Radiotherapy","Cervical Carcinoma",[576,577,578,579,580,581,582,583],"gynecological tumor","adaptive radiotherapy","radiation","curative treatment","optimization","adaptive radiation therapy","image guided radiotherapy","Cervical carcinoma","2024-02-07",{"date":586,"type":30},"2024-02-09",{"date":588,"type":30},"2024-01-15",{"date":590,"type":20},"2026-12-15",{"name":36,"class":37},{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":599,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":601,"conditions":602,"keywords":604,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":38},"100406336","fapi-pet-for-tumor-detection-100406336","NCT04571086","FAPI-PET for Tumor Detection","68-Ga-FAPI-PET for Tumor Detection: A Prospective Observational Trial","Inclusion Criteria:\n\n1. FAPI-PET scheduled for staging or restaging as part of clinical routine for proven or suspected malignancy\n2. Age ≥ 18 years.\n\nExclusion Criteria:\n\n1. Patient cannot give consent for the study\n2. Patient can not lie flat or tolerate FAPI PET imaging\n3. Unwillingness or inability to comply with study and follow-up procedures\n4. Condition of patient which is critical to participate in this study in the discretion of the investigators\n5. Pregnant, lactating, or breast feeding women.",{"count":600,"type":20},500,"This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET\u002FCT or PET\u002FMRI in patients receiving this imaging modality for tumor staging or restaging as part of clinical care.",[603],"Malignant Neoplasm",[605,400,606,607,608,609,610],"FAPI","Positron-Emission-Tomography","FAP","fibroblast","imaging","PET","2023-11-28",{"date":613,"type":30},"2023-11-29",{"date":615,"type":30},"2020-04-30",{"date":617,"type":20},"2027-04-30",{"name":36,"class":37},{"id":620,"slug":621,"hasResults":11,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":625,"eligibilityCriteria":626,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":627,"targetDuration":628,"studyType":22,"phases":4,"briefSummary":629,"conditions":630,"keywords":634,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":646,"locationsCount":269},"100482563","surgical-registry-of-endocarditis-europe-100482563","NCT05563662","SURgical Registry of ENDocarditis EuRope","SURgical Registry of Infective ENDocarditis in EuRope - SURRENDER","SURRENDER","Inclusion Criteria:\n\n* Patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery\n* Age ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Missing declaration of consent\n* Current participation in another interventional trial",{"count":536,"type":20},"5 Years","This is a prospective, multicentric, european registry of patients with infective endocarditis undergoing cardiac surgery. Patient demographics, clinical data and laboratory values will be collected, as well as treatment outcomes at day 30, day 90 and 1-5 years after the intervention.",[631,632,633],"Infective Endocarditis","Cardiac Surgery","Outcomes",[631,635,636,637,638],"Registry","European","Surgery","Prognosis","2023-05-09",{"date":641,"type":30},"2023-05-10",{"date":643,"type":20},"2023-09",{"date":645,"type":20},"2033-04",{"name":36,"class":37},{"id":648,"slug":649,"hasResults":11,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":653,"eligibilityCriteria":654,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":655,"targetDuration":4,"studyType":76,"phases":657,"briefSummary":658,"conditions":659,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":4},"100446003","allolife---life-after-transplantation-100446003","NCT05087784","AlloLife - Life After Transplantation","AlloLife - Life After Allogeneic Hematopoietic Stem Cell Transplantation","AlloLife","Inclusion Criteria:\n\n* Age \\> 18\n* Patients with performed allogeneic stem cell transplantation any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after HCT.\n* Hematologic Remission after HCT at study entrance, MRD positive patients are allowed to enter the study\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship to participate in the study\n* Access to an internet connected device (smartphone\u002Ftablet\u002Fcomputer)\n* Able to understand and communicate in the respective language\n* Consent to use a wearable device through the time of the study\n* Consent to use a chatbot application for both healthcare data exchange and psychologic intervention\n\nExclusion Criteria:\n\n* Missing consent to use a wearable device and contribute personal data collected at the point of life to the study\n* ECOG performance status of 4\n* Relapse of the disease at study inclusion\n* Uncontrolled systemic infection\n* Diagnosis of a secondary malignancy requiring systemic therapy\n* Reported ongoing severe depression or potential suicidal ideation\n* Vulnerable patients such as: minor, persons deprived of liberty, persons in Intensive Care Unit unable to provided informed consent prior to the intervention\n* Other ongoing interventional protocol that might interfere with the current study primary endpoint",{"count":656,"type":20},192,[78],"Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.",[542,660],"Stem Cell Transplant Complications","2021-11-08",{"date":663,"type":30},"2021-11-16",{"date":665,"type":20},"2024-03",{"date":667,"type":20},"2026-06",{"name":36,"class":37},""]